Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000556
First received: October 27, 1999
Last updated: March 24, 2016
Last verified: November 2005
  Purpose
To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.

Condition Intervention Phase
Arrhythmia
Atrial Fibrillation
Cardiovascular Diseases
Heart Diseases
Drug: amiodarone
Drug: sotalol
Drug: propafenone
Drug: flecainide
Drug: quinidine
Drug: moricizine
Drug: disopyramide
Drug: procainamide
Drug: adrenergic beta antagonists
Drug: verapamil
Drug: diltiazem
Drug: digoxin
Procedure: catheter ablation
Device: pacemaker, artificial
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: March 1995
Estimated Study Completion Date: September 2002
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   65 Years to 100 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
Elderly men and women with atrial fibrillation and other risk factors for stroke.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000556

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
OverallOfficial: H. Greene Statistics and Epidemiology Research Corporation (S.E.R.C.)
  More Information

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00000556     History of Changes
Other Study ID Numbers: 100 
Study First Received: October 27, 1999
Last Updated: March 24, 2016
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Atrial Fibrillation
Cardiovascular Diseases
Heart Diseases
Arrhythmias, Cardiac
Pathologic Processes
Amiodarone
Procainamide
Verapamil
Propafenone
Flecainide
Digoxin
Moricizine
Disopyramide
Quinidine
Sotalol
Diltiazem
Adrenergic Agents
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Vasodilator Agents
Potassium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Sodium Channel Blockers
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 CYP3A Inhibitors

ClinicalTrials.gov processed this record on December 06, 2016